Human Hepatitis B Immunoglobulin 500 IU

Therapeutic Indication:

Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment starts.

The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.

  • Composition: Human Hepatitis B Immunoglobulin 500 IU/ml
  • Pharmaceutical Form: Solution for Infusion.
  • Method of Administration: Intravenous.
  • How Supplied: Pack of 5x 1ml Prefilled Syringes.
  • Manufacturer: Biotest AG, Germany.

Contact Us

Contact us today to find out more about our services and discuss your enquiries.